The ThermoBreast project works on a modality that has a potential to be a safe and reliable tool for earlier breast cancer detection and prediction. And healthcare professionals have a crucial role in devising the ThermoBreast technology as a supplementary imaging method of a new generation. 

The ThermoBreast clinical study

ThermoBreast is a major ambitious European initiative. Its unique international clinical study will allow health policy makers to adopt better patient screening and monitoring programmes by including ThermoBreast as a supplementary imaging modality, resulting in a reduced rate of false negatives and overdiagnosis of other modalities in population-based screenings. As it will not be prone to human subjectivity and due to its seamless screening and automated analysis, ThermoBreast will also provide physicians with instant, unbiased answers to support their decision-making. In hospital settings, the ThermoBreast device will be located in a controlled-temperature room and operated by certified nurses and technicians. Trained staff will be conducting the whole process of the examination, adjusting it to the patient characteristics and ensuring the implementation of screening steps. Upon installation, it can screen 17 women per day, ultimately lessening the physical and mental strain of breast cancer patients and healthcare providers.

ThermoBreast screening procedure

Meet ThermoBreast clinical partners

ThermoBreast involves partners from all over Europe, with a variety of clinical sites based in different European countries, enabling the validation and implementation of the ThermoBreast technology to be applied to multiple healthcare systems and settings. Together, the clinical partners of the ThermoBreast consortium are pushing the project further and bringing us closer to our ultimate goal – safe and accurate screenings for early breast cancer detection and monitoring.

The clinicians involved in the ThermoBreast clinical study perform the following responsibilities:

  • Providing potentially eligible women with thorough information about participation in the clinical validation;

  • Verifying inclusion and exclusion criteria of women interested to participate;

  • Having eligible women sign a form of consent;

  • Assigning women to the study group (Screening or Diagnostic cohort);

  • Conducting the whole process of the examination, adjusting it to the patient characteristics and ensuring the implementation of screening steps;

  • Answering any questions potential participants may have about the study or their participation throughout the four years of follow-up.